-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Amid a notable positive session for the major equity indices, Biogen (NASDAQ:BIIB) really got the party started with a massive 37% boost in the early afternoon session on Wednesday. Biogen disclosed very encouraging results for its final-phase test for lecanemab, an experimental therapeutic for Alzheimer's disease. Given the breakthrough, other biotech stocks related to the condition jumped, including trial partner Eisai (OTCMKTS:ESALY) and sector rival Eli Lilly (NYSE:LLY).
The lecanemab therapeutic produced positive top-line results in Alzheimer's patients suffering from mild cognitive impairment, per the Motley Fool. Specifically, it "met the primary endpoint of significantly reducing the clinical decline" of key cognitive and functional metrics. In addition, the experimental treatment met certain secondary endpoints, including statistically significant benefits on cognition. Lecanemab removes built-up plaque in the brain called beta amyloid.
Naturally, the disclosure bolstered biotech stocks tied to Alzheimer's treatment due to the subsegment representing a clinical minefield. As the Washington Post mentioned in April 2020, the race for an effective treatment has been riddled with failure. "More than 200 promising leads have fallen through just in the past decade."
For Biogen, the current news is particularly sweet because it previously forwarded an Alzheimer's treatment called Aduhelm. However, Investor's Business Daily noted that "the benefits on cognition were dubious with one successful and one failed Phase 3 test."
In contrast, Mizuho Securities analyst Salim Syed described the results for lecanemab as "rather clean." At 18 months, for instance, "patients who received lecanemab showed a 27% slower decline in cognition compared with placebo recipients."
Biotech Stocks Rise, But Prudence Remains Vital
Based on historical challenges associated with Alzheimer's research and Biogen's own frustrations, Wall Street granted biotech stocks a massive lift. At the time of writing, ESALY skyrocketed 63% on Wednesday while LLY gained 8% — a tremendous performance for a blue chip.
SVB Securities analyst Marc Goodman weighed in on the news, suggesting that lecanemab should be clinically meaningful for patients. In turn, it could boost biotech stocks associated with treating Alzheimer's. "We expect that these positive results will reinvigorate the Alzheimer's disease space and increase the focus of the investor community for the two near-term anti-amyloid beta (drugs)," he said in a note.
Nevertheless, investors need to be cautious about getting too heavily involved in the aforementioned biotech stocks. Dr. Howard Fillit, chief science officer for the Alzheimer's Drug Discovery Foundation, stated that the results provided encouragement. However, the breakthrough only represents a first step in treating the disease.
"Amyloid-clearing drugs will provide an incremental benefit at best and there is still a pressing need for the next generation of drugs focused on other targets based on our knowledge of the biology of aging," he said in an emailed statement to Investor's Business Daily. "We are optimistic about the future as many of these drugs are in development."
Still, with the benchmark S&P 500 index down about 8% in the trailing month, Wall Street needed some good news. Investors got it in the form of Alzheimer's-associated biotech stocks.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post Biotech Stocks LLY, ESALY Gain on Biogen's Positive Trial Results appeared first on InvestorPlace.
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧